4/29/2023 0 Comments Blood type and covidThe rapid workflow from patients to target identification shows the usefulness of GWAS, a standardized research tool that often relies on international and interdisciplinary cooperation. Control data were obtained from control participants and from historical control data in Italy and Spain. All the obtained blood samples were centrally isolated, genotyped, and analyzed within 8 weeks. Samples from patients in three Italian hospitals (hospital A: Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan hospital B: Humanitas Clinical and Research Center, IRCCS, Milan and hospital C: UNIMIB School of Medicine, San Gerardo Hospital, Monza) and four Spanish hospitals (hospital A: Hospital Clínic and IDIBAPS, Barcelona hospital B: Hospital Universitario Vall d’Hebron, Barcelona hospital C: Hospital Universitario Ramón y Cajal, Madrid and hospital D: Donostia University Hospital, San Sebastian) were obtained around the peak of the local epidemics, and ethics applications were quickly obtained by means of fast-track procedures (i.e., every local ethics review board supported studies of coronavirus disease 2019 studies by providing rapid turn-around times, thus facilitating this fast de novo data generation). The main events and milestones of the study are summarized in the plot. Timeline of Rapid Covid-19 Genomewide Association Study (GWAS). (Funded by Stein Erik Hagen and others.) Introductionįigure 1. We identified a 3p21.31 gene cluster as a genetic susceptibility locus in patients with Covid-19 with respiratory failure and confirmed a potential involvement of the ABO blood-group system. The association signal at locus 9q34.2 coincided with the ABO blood group locus in this cohort, a blood-group–specific analysis showed a higher risk in blood group A than in other blood groups (odds ratio, 1.45 95% CI, 1.20 to 1.75 P=1.48×10 −4) and a protective effect in blood group O as compared with other blood groups (odds ratio, 0.65 95% CI, 0.53 to 0.79 P=1.06×10 −5). At locus 3p21.31, the association signal spanned the genes SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6 and XCR1. We detected cross-replicating associations with rs11385942 at locus 3p21.31 and with rs657152 at locus 9q34.2, which were significant at the genomewide level (P<5×10 −8) in the meta-analysis of the two case–control panels (odds ratio, 1.77 95% confidence interval, 1.48 to 2.11 P=1.15×10 −10 and odds ratio, 1.32 95% CI, 1.20 to 1.47 P=4.95×10 −8, respectively). In total, we analyzed 8,582,968 single-nucleotide polymorphisms and conducted a meta-analysis of the two case–control panels. After quality control and the exclusion of population outliers, 835 patients and 1255 control participants from Italy and 775 patients and 950 control participants from Spain were included in the final analysis. We conducted a genomewide association study involving 1980 patients with Covid-19 and severe disease (defined as respiratory failure) at seven hospitals in the Italian and Spanish epicenters of the SARS-CoV-2 pandemic in Europe. Genomewide association analysis may allow for the identification of potential genetic factors involved in the development of Covid-19. There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19). The most trusted, influential source of new medical knowledge and clinical best practices in the world. ![]() Information and tools for librarians about site license offerings. Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams. NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care. NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |